This may potentially free recipients from having to take anti-rejection medications, changing the lives of hundreds of thousands transplant recipients.
In order to qualify for this type of experimental kidney transplant, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection in the kidney.
The clinical trial is ongoing. Researchers are also planning a second clinical trial, which would offer similar treatment for subjects who have already undergone a living donor kidney transplant.
For more information about the study requirements, visit www.nmh.org/nm/transplant, or call 312-695-0828.
